67 studies found for:    Open Studies | "Hemophilia A"
Show Display Options
Rank Status Study
21 Not yet recruiting Patient Functioning and Well-being, Economic, and Clinical Impact of Hemophilia A and Its Treatment
Condition: Hemophilia A
Intervention: Drug: Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)
22 Recruiting Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A
Condition: Hemophilia A
Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product;   Biological: GreenGene™ F
23 Not yet recruiting A Study of a Long-Acting r-Factor 7a (Factor VIIa) in Adult Men With Hemophilia A or B
Conditions: Hemophilia A;   Hemophilia B
Intervention: Drug: MOD-5014
24 Recruiting To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
25 Recruiting Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
26 Recruiting Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant factor VIII (rFVIII)
27 Recruiting Phase 3b Continuation Study of the Safety and Efficacy of Prophylactic BAX 855 in PTPs With Severe Hemophilia A
Condition: Hemophilia A
Intervention: Biological: PEGylated Recombinant Factor VIII
28 Recruiting A Phase 1 Study of an Investigational Drug, ALN-AT3SC, in Healthy Volunteers and Hemophilia A or B Patients
Conditions: Hemophilia A;   Hemophilia B
Interventions: Drug: ALN-AT3SC;   Drug: Sterile Normal Saline (0.9% NaCl)
29 Not yet recruiting Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: Concizumab;   Drug: placebo
30 Recruiting A Prospective Study to Collect High-Quality Documentation of Bleeds Health-Related Quality of Life (HRQoL), and Safety Outcomes in Patients With Hemophilia A and Factor VIII (FVIII) Inhibitors Treated With Standard-of-Care Treatment
Condition: Hemophilia A
Intervention: Drug: Bypassing Agents
31 Recruiting Assess the Efficacy and Safety of Personalized Prophylaxis Human-cl rhFVIII in Patients With Severe Haemophilia A
Condition: Severe Haemophilia A
Intervention: Biological: Human cl rhFVIII
32 Not yet recruiting A Phase III Study on the Safety, Pharmacokinetics and Efficacy of Coagulation Factor VIIa (Recombinant) in Congenital Hemophilia A or B Patients From ≥6 Months Old to <12 Years Old With Inhibitors to Factor VIII or IX
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Intervention: Biological: Coagulation FVIIa (Recombinant)
33 Unknown  Personalized Prediction of Tolerance and Immunogenicity in Hemophilia
Condition: Hemophilia A
Intervention:
34 Not yet recruiting Hemophilia Inhibitor Prevention (INHIBIT) Trial
Condition: Severe Hemophilia A
Intervention: Drug: Long-acting recombinant factor VIII Fc fusion protein
35 Recruiting Covalent Tolerance Induction to Factor VIII-Prediction of Inhibitors in Hemophilia
Condition: Hemophilia A
Intervention:
36 Recruiting BAY81-8973 Pediatric Safety and Efficacy Trial
Condition: Haemophilia A
Intervention: Biological: Recombinant Factor VIII (BAY81-8973)
37 Unknown  Survey of Inhibitors in Plasma-Product Exposed Toddlers
Condition: Hemophilia A
Interventions: Drug: PLASMA DERIVED Factor VIII;   Drug: Recombinant FVIII
38 Recruiting Thrombin Generation Assay (TGA) as Predictive Test for Haemostatic. Effectiveness of FVIII Concentrates in Haemophiliac A With Inhibitors
Condition: Severe Hemophilia A With Inhibitor
Intervention: Other: TGA (Thrombin generation Assay)
39 Recruiting Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors
Conditions: Hemophilia A With Inhibitors;   Hemophilia B With Inhibitors
Interventions: Drug: CSL689;   Drug: Eptacog alfa (activated)
40 Unknown  A Prospective, Randomized, Cross-Over Study of an Activated Prothrombin Complex Concentrate for Secondary Prophylaxis in Patients With Hemophilia A and Inhibitors
Condition: Hemophilia A With Inhibitors
Intervention: Drug: activated prothrombin complex concentrate (FEIBA)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years